005690.KS Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 08:30):

Stats
Dagens volum	130 264
Gjennomsnittsvolum	696 933
Markedsverdi	345.02B
EPS	KRW0 ( 2024-02-12 )
Neste inntjeningsdato	( KRW0 ) 2024-05-12
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW10.68 (0.19%)

Volum Korrelasjon

Lang: -0.09 (neutral)

Kort: -0.56 (weak negative)

Signal:(45.231) Neutral

Pharmicell Co., Ltd. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Pharmicell Co., Ltd. Korrelasjon - Valuta/Råvare

0.34
( neutral )

0.29
( neutral )

-0.52
( weak negative )

0.02
( neutral )

-0.08
( neutral )

-0.14
( neutral )

Pharmicell Co., Ltd. Økonomi

Annual	2023
Omsetning:	KRW56.23B
Bruttogevinst:	KRW14.96B (26.60 %)
EPS:	KRW59.63

FY	2023
Omsetning:	KRW56.23B
Bruttogevinst:	KRW14.96B (26.60 %)
EPS:	KRW59.63

FY	2022
Omsetning:	KRW60.18B
Bruttogevinst:	KRW23.82B (39.58 %)
EPS:	KRW137.79

FY	2021
Omsetning:	KRW50.89B
Bruttogevinst:	KRW23.46B (46.09 %)
EPS:	KRW158.70

Financial Reports:

No articles found.

Pharmicell Co., Ltd.

Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to enhance the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; and Cellgram_DC, a cancer drug, as well as Hearticellgram_AM, a cardiac disease drug. It also develops and produces intermediates of raw material medicines, such as nucleosides, mPEGs, HDP-tosylate, and vincelactam; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company operates Twelve, a stem cell bank; develops and sells stem cell culture media cosmetics. Pharmicell Co., Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.